Cadrenal Therapeutics (CVKD) Cash from Financing Activities (2022 - 2026)

Cadrenal Therapeutics has reported Cash from Financing Activities for 5 years, with the latest figure at $1.3 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 33.88% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (down 45.85% YoY) and the FY2025 annual result came in at $6.6 million, down 26.54% from the prior year.
• Cash from Financing Activities declined to $1.3 million in Q1 2026 per CVKD's latest filing, from $2.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $7.5 million in Q4 2024 and troughed at -$12500.0 in Q4 2023.
• A 5-year average of $2.0 million and a median of $1.3 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities tumbled 105.69% in 2023, then jumped 661019.46% in 2025.
• Over 5 years, Cash from Financing Activities stood at $219721.0 in 2022, then slumped by 105.69% to -$12500.0 in 2023, then jumped by 59710.28% to $7.5 million in 2024, then sank by 63.53% to $2.7 million in 2025, then tumbled by 52.07% to $1.3 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.3 million, $2.7 million, and $648355.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.